Vendor Intelligence Report: NextGen Health

Published 13 Jun 2026. 22-page investigative report on who is behind NextGen Health: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 3 Finnrick lab tests, NextGen Health has 3 pass / 0 fail, an overall pass rate of 100%. That clean record is narrow: every Finnrick-tested sample in this dossier is Tirzepatide. For a Tirzepatide buyer, the vendor is a reasonable candidate if the current lot can be verified; for other compounds, Finnrick coverage is absent and confidence should not be borrowed across the catalog.

The investigation is not an anonymous-vendor story. Florida filings tie the operation to Daniel Navarrete and related entities, with a sister fitness brand in the same orbit. The sharper issue is chronology: formation records, WHOIS and archive captures support a much newer public peptide storefront than the site’s “founded in 2022” and large-order-history marketing implies.

COA provenance is mixed. The library includes verifiable independent-lab signals, including ILS Laboratories material and Freedom Diagnostics database evidence, but it also publishes BioRegen/BioInfinity QA documents for certain products; the report shows why those documents should not be treated the same as independent third-party testing.

Buyer risk also sits around reputation and promotion. Trustpilot removed the ngpeptide.com profile for guideline violations, the reason is not public, and lookalike NextGen domains create practical attribution risk. Finnrick’s network sweep found an official partner program and referral-code promotions across social and coupon channels, often without clear disclosure.

Inside the full report:

  • Per-product pass/fail detail, rating trajectory and methodology-divergence charts for the tested Tirzepatide record
  • Florida Sunbiz filings linking NEXTGEN PEPTIDES, LLC, NG PERFORMANCE SOLUTIONS LLC and historical entities to the operator
  • WHOIS and Wayback evidence comparing public history claims with the storefront’s verifiable launch timeline
  • COA provenance analysis separating ILS/Freedom Diagnostics documents from BioRegen/BioInfinity QA material
  • Affiliate and referral-code scan across X, Reddit, coupon pages and the vendor partner program
  • Review-integrity and brand-confusion assessment covering Trustpilot removal, PeptideCritic, PeptideBenchmark and similar NextGen domains

Risk assessment

  • Non-independent COA provenance risk — high: COA library for 5-Amino-1MQ, AOD9604 and Cagrilintide includes BioRegen/BioInfinity QA documents; evidence suggests manufacturer or competitor-branded documentation rather than independent third-party testing.
  • Review-integrity and complaint-pattern risk — high: Trustpilot removed the ngpeptide.com profile for guideline violations; PeptideCritic shows 2.3/5 from 3 reviews with unverified Cagrilintide and Epithalon complaints.
  • Affiliate-promotion risk — high: Official partner program plus scan of 18 promoters found 15 referral or code placements, with 12 referral-carrying promoters lacking clear disclosure.
  • Copycat and brand-confusion risk — high: Similar NextGenPeps domains carry scam-warning traffic; the record does not show an authorized-reseller or anti-counterfeit list sufficient to separate ngpeptide.com from lookalikes.
  • Misleading history and contact-footprint risk — medium: Website claims founded in 2022, 3+ years and 75,000+ orders, but domain and archive records support a March 2025 launch and Florida LLCs formed in 2026.